Vivo Capital is a healthcare focused investment firm formed in 1996 with over $1 billion* under management. Vivo Capital is currently making investments from its $375M seventh fund into promising private and public healthcare companies in the U.S. and greater China.

Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Shanghai, China, and Chengdu, China.

With over 100 years of scientific expertise and operating experience in healthcare, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth. Vivo’s current portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.
The Medicines Company Acquires Rempex Pharmaceuticals
Parsippany, NJ and San Diego, CA -
December 4, 2013

* As of December 31, 2013